Amarin hasn’t stopped astonishing analysts.
Five weeks after the company offered a big thumbs-up to its 7-year REDUCE-IT cardio study of Vascepa, with more than 8,000 patients, researchers showed up at the annual science meeting of the AHA with a battery of highly positive results for a slew of secondary endpoints.
But the latest, detailed update also raised a royal ruckus over the weekend over what exactly caused the positive effect, a single significant safety data point to consider and whether the company stacked the deck in its favor with the mineral oil it used in the placebo. And that has the company's shares in the red early Monday.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.Free Subscription